highly significantP < 0.0001
Among patients treated with sarilumab or tocilizumab, the difference in survival between the high- and low-risk groups was highly significant ( P < 0.0001).
Among patients treated with sarilumab or tocilizumab, the difference in survival between the high- and low-risk groups was highly significant ( P < 0.0001).